Lerolimab will probably be approved as a combo at

Lerolimab will probably be approved as a combo at the latest by the beginning of 2020, meaning 6-7 months.
CYDY has lowered the price for Leronlimab to $ 35,000 and as soon as it is approved for the combo, it is likely that the off-label will be massively used as a mono due to reduced prices and its benefits.
The NP said that BP returned to the negotiating table. That's logical because Leronlimab has become competitors with combo approval because of the off-label usage.
If interim results for mTNBC are very good, the space for Leronlimab off-label use for cancers is opened.

Now, I have the problem of getting a partnership for HIV and separating it from cancers. Negotiations with BP are complicated due to Leronlimab's success in many indications.

I consider that for Gilead this partnership or BO is now very important because it remains only 6-7 months until the approval of Leronlimab.

Indication for HIV is pre-approved and is ready for partnership or BO, and yet more powerful indication for cancers yet to start testing on humans, this is the matter of negotiating how to break it apart.

My assessment is that some kind of co-operation with BP will be accomplished in the next month or two.